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O18 RESPONSE TO TERIPARATIDE TREATMENT DIFFERS BY ANATOMICAL SITE AND BONE 
COMPARTMENT Margaret A Paggiosi1 , Lang Yang1 , Daniel Blackwell1 , Jennifer S Walsh1 , Eugene 
McCloskey1 , Nicola Peel2 , Richard Eastell1 1 The University of Sheffield, Sheffield, UK, 2 Sheffield 
Teaching Hospitals NHS Foundation Trust, Sheffield, UK  
 
Background: Teriparatide, a licensed anabolic treatment for severe osteoporosis, stimulates bone 
formation and resorption. It has the potential to exert distinct effects on different bone 
compartments. Large increases in spine bone mineral density (BMD) occur during teriparatide 
treatment, but concomitant effects on the peripheral skeleton are not well described. 
Objective: To characterise the central and peripheral skeleton using imaging techniques to better 
understand the mechanism of action of teriparatide. 
Methods: Osteoporotic postmenopausal women (n = 20, 65.4 ± 5.5 years, BMD T-ƐĐŽƌĞчо ? ? ?ĂƚƚŚĞ
total hip or lumbar spine by dual energy x-ray absorptiometry (DXA)) were recruited to an open label 
study of subcutaneous teriparatide (Forsteo 20 mcg daily) for 104 weeks. Total and sub-total bone 
mineral content (BMC) were measured by DXA (Discovery A). Radius and tibia volumetric BMD 
(vBMD) and microstructural properties were assessed by high resolution peripheral quantitative 
computed tomography (XtremeCT) using standard and extended cortical bone analyses. Trabecular 
bone structure of vertebra T12 was studied using high-resolution quantitative computed 
tomography (GE Lightspeed). 
Results: By week 104, no significant change in total or subtotalbody BMC was detected. Lumbar 
spine (p= 0.0001) and pelvis (p= 0.0005) BMC had increased but there was a decrease in skull (p= 
0.008) and arm (p< 0.01) BMC. Peripheral changes included a significant decrease in cortical vBMD 
 ?ƌĂĚŝƵƐŵĞĂŶĐŚĂŶŐĞсо ? ? ?й ?Ɖс ? ? ? ? ?ƚŝďŝĂŵĞĂŶĐŚĂŶŐĞсо ? ? ? й ?Ɖс ? ? ? ? ? ?ĂŶĚĐŽƌƚŝĐĂůƚŝƐƐƵĞ
ŵŝŶĞƌĂůĚĞŶƐŝƚǇ ?dD ? ?ƌĂĚŝƵƐŵĞĂŶĐŚĂŶŐĞсо ? ? ?й ?Ɖс ? ? ? ? ? ?ƚŝďŝĂŵĞĂŶĐŚĂŶŐĞсо ? ? ?й ?Ɖс
0.0006). Cortical porosity increased at the radius (mean change = +18.8 %, p = 0.007) and tibia (mean 
change = + 10.3 %, p = 0.05) but cortical pore diameter remained unchanged. There were no 
statistically significant changes in radius and tibia trabecular bone parameters. Within T12 there was 
an increase in trabecular number and thickness (mean change = +32.0 % and +24.0 % respectively, 
p< 0.05). 
Conclusion: The mechanism of action of teriparatide to increase BMC within the central skeleton is 
through an increase in trabecular number and thickness. In contrast, within the peripheral skeleton, 
treatment decreases BMD through a reduction in cortical TMD and an increase in cortical porosity. 
 
